Related references
Note: Only part of the references are listed.Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
Maurizio Brausi et al.
EUROPEAN UROLOGY (2014)
Bacillus Calmette-Guerin immunotherapy for genitourinary cancer
Nilay M. Gandhi et al.
BJU INTERNATIONAL (2013)
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Marko Babjuk et al.
EUROPEAN UROLOGY (2013)
Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
Jorg Oddens et al.
EUROPEAN UROLOGY (2013)
The Efficiency of the EORTC Scoring System for the Prediction of Recurrence and Progression of Non-muscle-invasive Bladder Cancer Treated by Bacillus Calmette-Guerin Immunotherapy
Faouzia Ajili et al.
ULTRASTRUCTURAL PATHOLOGY (2013)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
Richard J. Sylvester et al.
EUROPEAN UROLOGY (2010)
An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer
Per-Uno Malmstrom et al.
EUROPEAN UROLOGY (2009)
Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials
Rui Fa Han et al.
UROLOGY (2006)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
The cost of bladder tumour treatment and follow-up
H Hedelin et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2002)
A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
MD Shelley et al.
BJU INTERNATIONAL (2001)
Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin
M Brake et al.
JOURNAL OF UROLOGY (2000)
Share Paper
